Yatiri Bio

Executive Summary

Yatiri Bio is a privately held biotechnology company headquartered in Cambridge, MA, founded in 2020 with a focus on developing novel immunotherapies and targeted therapies for cancer. The company distinguishes itself by integrating advanced proteomics and deep learning to build predictive models that improve patient selection and therapeutic strategy. By analyzing the proteins driving disease biology, Yatiri aims to bridge the translational gap between drug discovery and clinical success, matching patients with the most effective treatments. While the company is early-stage and has not disclosed specific pipeline candidates or funding, its platform-based approach leveraging AI-driven proteomics positions it within the rapidly growing precision oncology and immunology space. The lack of public financial data or clinical milestones to date introduces significant uncertainty, but the founding team's location in Cambridge suggests access to top-tier talent and research ecosystems.

Upcoming Catalysts (preview)

• Q4 2026Series A funding announcement60% success
• H1 2027Preclinical proof-of-concept data for lead program40% success
• Q2 2027Key partnership with pharma or academic institution30% success